secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001558370-25-007253
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Q1 net loss $7.3M; completes first cohort enrollment in PRECISE-AD trial
-------------------------------------------------------------------------------

- Net loss $7.3M vs $3.6M YoY; R&D expense $5.5M on PMN310 Phase 1b trial costs.
- Cash $8.4M at March 31, 2025, down from $13.3M at Dec 31, 2024.
- First cohort fully enrolled and dosed in PRECISE-AD (Phase 1b) for PMN310 in Alzheimer's.
- Six-month interim results expected 1H 2026; topline data by end of 2026.
- PRECISE-AD designed to detect ARIA with 95% confidence; powered for biomarker changes at 6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/0001558370-25-007253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/pmn-20250512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer